BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the shares. The firm had previously indicated that shares had ...

Vertex, Inc. (NASDAQ:VERX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports.

Federal Territory of Kuala Lumpur, Malaysia, February 28, 2025 -- SurgeGraph, an AI writing tool focused on helping users ...

Fintel reports that on February 28, 2025, Stifel downgraded their outlook for Vertex (NasdaqGM:VERX) from Buy to Hold.

The stock's rise snapped a four-day losing streak.

In Vermont, no day goes by without another news story about the lack of affordable, workforce, and senior housing.

April users can now file in all 50 states; KSM launches IT services advisory; Expensify announces Expensify Travel; and other accounting tech news and updates.

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...